Posted on November - 14 - 2011
FDA assigns new PDUFA date for Takeda’s investigational type 2 diabetes therapy, alogliptin
“Takeda is confident in alogliptin and alogliptin/pioglitazone as potential therapeutic options for the millions of patients living with type 2 diabetes,” said
Alogliptin is a highly potent and highly selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the U.S. for the treatment of type 2 diabetes as an adjunct to diet and exercise.
There is no change in Takeda’s fiscal 2011 financial outlook, which was announced on
Similar Posts:
- Statins Increase the Risk of Type 2 Diabetes
- 4 Tips to Organizing and Sticking to a Healthy Eating Plan
- Every child tested for cholesterol, doctors recommend
- Tell dad to make exercise priority
- Tell dad to make exercise priority
